Zolodrenic acid can prevent early bone loss in HIV patients on antiretroviral therapy

A single dose of the drug zoledronic acid was found to inhibit the bone loss that is common in HIV-infected patients and that is increased during the first two years of treatment with antiretroviral therapy. Bone loss also leads to a higher rate of fracture in HIV-infected individuals.